[ad_1]
If they are convincing, the large-scale manufacture of an AIDS vaccine will be launched. In a statement from The Lancet, researchers reported Saturday, July 7 encouraging progress.
Study released this Saturday reports results a test of 393 healthy, seronegative adults aged 18-50 in East Africa, South Africa, Thailand and the United States. Guinea pigs received different versions of the vaccine or placebo at four injections in 48 weeks. But this one was " robust ", welcomes the director of the study, the virologist Dan Barouch. The solution to find a vaccine to fight this disease is extremely difficult, but a recent study shows that a vaccine, which has been tested in monkeys and in humans, shows encouraging results . Only five participants reported adverse effects. Of the 72 macaques in the trial, more than two-thirds were protected from the virus when they were transmitted. "Joined by other experts, however, he warned that there was no guarantee that the following tests are as positive." The results of this test are expected for 2021 or 2022. An experimental vaccine would have had inconclusive results on macaques. The risk of infection of 16,000 volunteers in Thailand had been reduced by only 31%. The other vaccines were limited to specific versions of HIV concentrated in certain regions of the world.
Underlined Professor Dan Barouch. For specialists, developing a vaccine capable of fighting against HIV infection will be made possible within ten years . For Frenchman Jean-Daniel Lelièvre, of the Vaccine Research Institute: "This is probably not the definitive vaccine, but it can be a phenomenal advance."
According to him, "in the best case, "this research will produce a manageable vaccine in" almost 10 years. "
According to the World Health Organization, nearly 37 million people are living with HIV or AIDS. The disease has killed an estimated 35 million of the 80 million people it has infected since it was diagnosed for the first time in the early 1980s.
[ad_2]
Source link
